Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Helical tomotherapy plus cetuximab followed by adjuvant docetaxel/cisplatin for locally advanced nasopharyngeal carcinoma
ChiCTR-OCC-15005888Phase 2Completed
- Sponsor
- Chinese PLA General Hospital
- Start
- Jan 1990
- Modality
- Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of cetuximab, cisplatin and docetaxel in nasopharyngeal carcinoma (NPC), sponsored by Chinese PLA General Hospital. Primary endpoints: Safety and Overall survival. Started Jan 1990; status: completed.
02
Drugs
cetuximabcisplatindocetaxel
03
Conditions
nasopharyngeal carcinoma (NPC)
Beyond the preview
Go deeper on ChiCTR-OCC-15005888.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR-OCC-15005888.